05:21 AM EDT, 07/20/2026 (MT Newswires) -- Sareum Holdings (SAR.L) said Monday it completed dosing in the phase 2-enabling toxicology program for its autoimmune disease drug candidate SDC-1801, which is initially focusing on psoriasis. The British biotechnology company is using existing cash to evaluate the resulting data and to conduct chemistry, manufacturing, and controls and formulation development activities. The full phase 2-enabling regulatory package is on course for completion by the fourth quarter.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.